CALL UPDATE: GENERALISED FEEDBACK AFTER STAGE 1

GENERALISED FEEDBACK FOR SUCCESSFUL APPLICANTS AFTER STAGE 1

Call for proposals: PERSONALISED MEDICINE (H2020-SC1-2016-2017)
Published: 14.10.2015
Deadline: 04.10.2016

The stage 1 evaluation is now finished.

Statistics for the call are available via the flash call info update on the Participant Portal.

In order to best ensure equal treatment, successful stage 1 applicants do not receive the evaluation summary reports (ESRs) for their proposals, but this generalised feedback with information and tips for preparing the full proposal.

Information & tips

Main shortcomings found in the stage 1 evaluation:

- The use of stakeholder and end-user knowledge (such as patients and/or health care professionals) should be better integrated, since such knowledge is essential for the success of actions in this area.
- Many proposals had insufficient references to a gender/sex analysis, although the differences between men and women need to be taken into account in this/these topic(s).
- In terms of innovation potential, there was sometimes insufficient indication of the current state-of-the art, the published evidence already available and/or products, processes and services already on the market.
- Some proposals should better address all the expected impacts set out in the work programme.
- It is important for proposals to include more preliminary data. This helps for example to evaluate the innovation potential.
- The concept should be well described, including sufficient details.
- In drafting the proposal the applicants should make sure to address all of the individual sub-criteria for all evaluation criteria and to do so in the appropriate place. Even if it has been addressed at a different place within the proposal, it has to be referenced or repeated in the appropriate place to make it clear to the evaluator that the sub-criterion has been discussed.

- In stage 2 proposals it will be even more important than in stage 1 to include sufficient details on regulatory issues, including references to existing disease-specific (and e.g. statistical) guidance from regulatory authorities, documented interaction with regulatory authorities and/or sufficient consideration of a regulatory plan to pursue. For clinical trials this should be done in the specific template foreseen for this (see below).

- Several proposals, particularly in the area of clinical trial might contain over-optimistic estimates, in particular with regard to timelines and patient recruitment numbers. If evaluators consider these estimations as not sufficiently justified and over-optimistic, this will lead to negative influence on the scores. Please also note that there is no possibility to correct these timelines and patient recruitment numbers downward during the preparation of the grant agreement or later in amendments. Non-compliance with expected timelines and recruitment estimates will lead to termination of the grant agreement and reduction of the maximum grant amount.

- If your proposal contains clinical trials, studies or investigations, please study carefully the guidance on 'Essential information for clinical trials/studies' that is published on the call website on the Participant Portal (http://ec.europa.eu/research/participants/data/ref/h2020/other/legal/templ/h2020_tmpl-clinical-studies_en.pdf) and please remember to upload the related template that is available in the Participant Portal.

- Future grant agreements in SC1 will by default be part of the 'open data' approach (Art. 29.3 Model Grant Agreement). While the full data management plan will be an early deliverable in your proposal, please provide already at the full proposal stage some basic structure and principles of data management in your project, in particular on open data access and restrictions thereof. Please see here: http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/oa_pilot/h2020-hi-oa-data-mgt_en.pdf FAIR Data Management Guidelines.

In your stage 2 proposal, you have a chance to address or clarify these issues.

Please bear in mind that your full proposal will now be evaluated more in-depth and possibly by a new group of outside experts.

⚠ The full proposal must be consistent with your short outline proposal. It may NOT differ substantially. The project must stay the same.